Citations

Clear

17 citation(s) found for "Marcotte, F".

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials
Renfro, Lindsay A., Wu, Yue, Marcotte, Erin, Trippett, T, Horton, Terzah, Keller, Frank G., Forlenza, Chris, Schwartz, Cindy, Kelly, Kara M., Cole, Peter D., Castellino, Sharon M., Kahn, Justine M., Marcotte, Erin L. , Heneghan, Mallorie B. , Crisler, Katia M. , Trippett, Tanya, Horton, Terzah M. , Hoppe, Bradford S. , Keller, Frank G. , Schwartz, Cindy L. , Kelly, Kara M. , Castellino, Sharon M. , Kahn, Justine M

Mayo Clinic

Pediatric Blood & Cancer | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/1545-5017.70522 | PMID 42496647 Get It

ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and Hispanic (vs. non‐Hispanic White [NHW]) patients experienced higher post‐relapse mortality. It is unknown whether post‐relapse disparities persist when second‐line treatment is delivered in a cooperative group trial setting. We examined overall survival (OS) by race and ethnicity in CAYAs enrolled in COG trials for relapsed/refractory (r/r) cHL. Methods A pooled analysis of individual‐level data from CAYAs (≤ 29 years) receiving therapy for r/r cHL on COG clinical trials (2001–2016) was conducted. The Kaplan–Meier method estimated 3‐year OS by racial and ethnic groups. Cox regression models examined associations of race and ethnicity and OS, adjusted for age, insurance, first versus ≥2 relapse, and time from initial diagnosis to relapse trial enrollment. Results Among 175 CAYAs treated on COG trials for r/r cHL (5.7% Asian or Pacific Islander, 14.9% Hispanic, 14.3% NHB, 61.7% NHW, 3.4% other), at median follow‐up of 4.9 years, 3‐year OS was 82.1% (95% confidence interval [CI], 75.3%–87.1%) and did not differ by race and ethnicity ( p = 0.36). In multivariable analyses, shorter time from diagnosis to relapse trial enrollment ( p = 0.01) and ≥2 relapses (vs. first, p = 0.004) conferred worse OS, with no significant effect of race and ethnicity ( p = 0.43). Conclusion Post‐relapse survival did not differ by race and ethnicity among CAYAs enrolled in COG trials for r/r cHL, suggesting access to clinical trials may mitigate OS disparities.
An Uncommon Cause of Angina
Majdalany, David , Blickenstaff, Elaina A. , Marcotte, François , Anderson, Jason , Majdalany, David S , Anderson, Jason H. , Anderson, Jason H., Blickenstaff, Elaina A.

Mayo Clinic

Diagnostics | September 4, 2025 | Volume: 15 | Issue: 17 | Pages: 2241

10.3390/diagnostics15172241 | PMID 40941728 Get It

Coronary anomalies, although rare, should be considered when young patients present with angina. Clinical suspicion and multi-modality imaging including coronary angiography and tomographic imaging should be pursued for symptomatic patients such as the one we are presenting with anomalous right coronary artery from the pulmonary artery. She was promptly referred for surgical intervention with re-implantation of the right coronary artery onto the aorta.
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis
Kawtharany, Hassan , Azzam, Muayad , Alkhader, Aseel, Betensky, Marisol , Hamarsha, Qais, Mansour, Razan , Tabak, Carine , Bhat, Rukhmi , Biss, Tina , Brandão, Leonardo R. , Chan, Anthony K.C. , Faustino, E. Vincent S. , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A. , Pelland‐Marcotte, Marie‐Claude , Raulji, Chittalsinh M , Sartain, Sarah E. , Ommen, C. Heleen van , Wiernikowski, John , Williams, Suzan , Wilson, Hope P. , Woods, Gary , Zia, Ayesha , Abou Zeid, Hadi K, Brandão, Leonardo R , Chan, Anthony K C , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A , Kucine, Nicole , Male, Christoph , Pelland-Marcotte, Marie-Claude , Raffini, Leslie , Raulji, Chittalsinh M , Tarango, Cristina , van Ommen, C Heleen , Velez, Maria C , Vesely, Sara K , Zia, Ayesha , Monagle, Paul , Mustafa, Reem A , Kawtharany, Hassan , Hamarsha, Qais , Zeid, Hadi Khaled Abou , Patel, Payal Mukesh , Baghdadi, Sarah L., Bercovitz, Rachel S. , Branchford, Brian R. , Kumar, Riten , Takemoto, Clifford M.

Mayo Clinic

Blood Advances | June 25, 2025 | Volume: 9 | Issue: 21 | Pages: 5512-5527

10.1182/bloodadvances.2025017058 | PMID 40561511 Get It

Abstract We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation vs anticoagulation alone in pediatric patients with venous thromboembolism (VTE). This systematic review addresses mortality, VTE resolution, recurrence, bleeding, and organ-specific outcomes in 5 PICO (population, intervention, comparison, outcomes) questions on thrombolysis across pulmonary embolism (PE), extremity deep vein thrombosis (DVT), right atrial thrombosis (RAT), cerebral sinus venous thrombosis (CSVT), and renal vein thrombosis (RVT). Meta-analysis reported risk ratios or differences (95% confidence intervals [CIs]), and absolute effects per 1000 patients. Certainty of evidence was assessed using GRADE (Grading of recommendation, assessment, Development, and Evaluation) guidelines. Thirteen nonrandomized studies were included and no randomized clinical trials addressed these questions. Thrombolysis might be associated with a higher risk of major bleeding, clinically relevant nonmajor bleeding, or unspecified bleeding with risk differences of 0.09 (95% CI, −0.06 to 0.23), 0.06 (95% CI, −0.11 to 0.22), and 0.09 (95% CI, −0.04 to 0.23), respectively. In PE with hemodynamic compromise, thrombolysis might be associated with a lower risk of mortality but conclusions on PE progression were uncertain in submassive PE. In DVT, thrombolysis may have little to no effect on mortality or thrombus resolution but might be associated with lower risk of postthrombotic syndrome. In RAT, thrombolysis might have little to no effect on thrombus resolution but a higher risk of major bleeding and mortality. For CSVT and RVT, the evidence was very limited. These findings were based on very-low-certainty evidence because of confounding and imprecision from small sample sizes. This systematic review highlights key challenges in developing recommendations for thrombolysis in children with VTE.
Pulmonary Artery Dissection: Less Is Better When You Are Blue
Abdou, Merna , Shipman, Justin , Marcotte, François , Jokerst, Clinton E. , Majdalany, David , Jokerst, Clinton , Majdalany, David S

Mayo Clinic

Korean Circulation Journal | October 15, 2024 | Volume: 54 | Issue: 12 | Pages: 868

10.4070/kcj.2024.0212 | PMID 39506185 Get It

“Unkinking” the “Kink” Normalizes the Doppler Pattern
Blickenstaff, Elaina A. , O’Shea, Michael , Barry, Timothy , Arsanjani, Reza , Fasolino, John P., Hagler, Donald J. , Marcotte, François , Majdalany, David , Majdalany, David S , Hagler, Donald J , Arsanjani, Reza , Blickenstaff, Elaina A.

Mayo Clinic

Diagnostics | July 18, 2024 | Volume: 14 | Issue: 14 | Pages: 1550

10.3390/diagnostics14141550 | PMID 39061687 Get It

Coarctation of the aorta (CoA) comprises 5–7% of congenital heart disease and can present as an isolated narrowing in the aortic arch just distal to the left subclavian artery or can be associated with cardiac abnormalities such as a bicuspid aortic valve, aortopathy, or ventricular septal defects. With the advances in the medical field, intervention on CoA can either be via surgical repair or endovascular stenting. Echocardiography is the mainstay in diagnosing CoA, with tomographic imaging such as magnetic resonance imaging (MRI) or computed tomography providing supplementary assessment of the aorta, valves, and collateral vessels. We present a case of a young hypertensive male who was noted to have a continuous cardiac murmur with diagnostic Doppler pattern of CoA on echocardiography that normalized soon after percutaneous stenting.
High Lp(a) levels are a potential risk factor for aortic valve interventions in patients with bicuspid aortic valve
Farina, J M, Abbas, Moncef, Mahmoud, Ahmed K., Lester, S.C., Barry, Timothy, Marcotte, F, Pereyra, Milagros , Pereyra, Milagros , Arsanjani, Reza , Kamel, M A, Abbas, M T, Scalia, Isabel G. , Mahmoud, Ahmed , Ali, N Baba, Ayoub, C, Sell‐Dottin, Kristen , Alsidawi, Said , Lester, S, Majdalany, David S

Mayo Clinic

European Journal of Preventive Cardiology | June 14, 2024 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwae175.359 Get It

Abstract Background Bicuspid aortic valve (BAv) is associated with increased oxidative stress and inflammation, resulting in valve fibrosis, calcification, and ultimately early degenerative valve disease, often necessitating premature aortic valve intervention. In recent years, growing evidence has been published supporting the role of lipoprotein(a) [Lp(a)], an important carrier of oxidized phospholipids, in the development of aortic valve disease in the general population. However, the specific influence of Lp(a) levels in patients with BAv remains to be firmly established. Purpose To assess the role of Lp(a) levels in the development of aortic valve disease and the necessity for aortic valve interventions among individuals with BAv. Methods This retrospective multicenter study encompassed consecutive patients diagnosed with BAv from January 1997 to December 2022, all of whom had undergone serum Lp(a) measurement. This study evaluated the association between Lp(a) concentrations and the occurrence of aortic valve interventions. A cutoff point of ≥30 mg/dl for high Lp(a) levels was established. Binary logistic regression was utilized to calculate the odds ratio (OR) for an aortic intervention according to high versus low Lp(a) levels. Additionally, Kaplan Meier curves were employed to estimate the cumulative requirement for an aortic valve replacement based on Lp(a) concentrations. Results A total of 452 patients with BAv and a Lp(a) measurement were included in the study, with a mean age of 37.2 ±10.5 years at the time of BAv diagnosis, with 71.2% being male. Among these, 101 (22.3%) patients underwent an aortic valve replacement. In 72 cases (71.3%) aortic stenosis was the primary indication for intervention, while aortic regurgitation accounted for 29 cases (28.7%). The presence of elevated Lp(a) levels (≥30 mg/dl) demonstrated a significant association with the requirement for an aortic valve intervention (OR 2.2, 95%CI 1.4-3.6, p<0.001) in both the regression analysis and using the Kaplan-Meier estimator (Figure). High Lp(a) concentrations posed a risk factor for aortic valve replacements regardless of whether the primary indication for intervention was significant stenosis (OR 1.8, 95%CI 1.1-3.1, p=0.028) or regurgitation (OR 2.5, 95%CI 1.2-5.4, p=0.018). Conclusion Increased concentrations of Lp(a) may influence the clinical trajectory of patients with a BAv and may be a significant risk factor for aortic valve replacement, irrespective of the primary indication for intervention. Further investigations will be critical in unveiling the precise pathological mechanisms of Lp(a) in BAv. Confirming whether reducing Lp(a) levels could slow the progression of aortic disease in this demographic requires further exploration. Kaplan-Meier estimator.
Human myofiber‐enriched aging‐induced lncRNA FRAIL1 promotes loss of skeletal muscle function
Miller, Matthew J. , Gries, Kevin J. , Marcotte, George R. , Ryan, Zachary, Strub, Matthew D. , Arendt, Bonnie K., Dasari, Surendra , Adams, Christopher M. , Lanza, Ian R , Adams, Christopher M , Kunz, Hawley , Ebert, Scott M. , Lanza, Ian R.

Mayo Clinic

Aging Cell | February 1, 2024 | Volume: 23 | Issue: 4 | Pages: No page available

10.1111/acel.14097 | PMID 38297807 Get It

Abstract The loss of skeletal muscle mass during aging is a significant health concern linked to adverse outcomes in older individuals. Understanding the molecular basis of age‐related muscle loss is crucial for developing strategies to combat this debilitating condition. Long noncoding RNAs (lncRNAs) are a largely uncharacterized class of biomolecules that have been implicated in cellular homeostasis and dysfunction across a many tissues and cell types. To identify lncRNAs that might contribute to skeletal muscle aging, we screened for lncRNAs whose expression was altered in vastus lateralis muscle from older compared to young adults. We identified FRAIL1 as an aging‐induced lncRNA with high abundance in human skeletal muscle. In healthy young and older adults, skeletal muscle FRAIL1 was increased with age in conjunction with lower muscle function. Forced expression of FRAIL1 in mouse tibialis anterior muscle elicits a dose‐dependent reduction in skeletal muscle fiber size that is independent of changes in muscle fiber type. Furthermore, this reduction in muscle size is dependent on an intact region of FRAIL1 that is highly conserved across non‐human primates. Unbiased transcriptional and proteomic profiling of the effects of FRAIL1 expression in mouse skeletal muscle revealed widespread changes in mRNA and protein abundance that recapitulate age‐related changes in pathways and processes that are known to be altered in aging skeletal muscle. Taken together, these findings shed light on the intricate molecular mechanisms underlying skeletal muscle aging and implicate FRAIL1 in age‐related skeletal muscle phenotypes.
Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
Mahmoud, Ahmed , Abbas, Mohammed Tiseer , Kamel, Moaz, Farina, Juan M. , Pereyra, Milagros , Scalia, Isabel G. , Barry, Timothy , Marcotte, François , Scott, Robert L. , Majdalany, David , Arsanjani, Reza , Kamel, Moaz A, Majdalany, David S , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Mahmoud, Ahmed K , Scalia, Isabel G , Abbas, Mohammed Tiseer , Chao, Chieh‐Ju

Mayo Clinic

Journal of Personalized Medicine | December 20, 2023 | Volume: 14 | Issue: 1 | Pages: 5

10.3390/jpm14010005 | PMID 38276220 Get It

Current management of patients with congenital heart disease has increased their survival into adulthood. This is accompanied by potential cardiac complications, including pulmonary hypertension associated with congenital heart disease (PAH-CHD). PAH-CHD constitutes a challenging subgroup of pulmonary hypertension and requires expert management to improve quality of life and prognosis. Novel agents have shown a significant improvement in morbidity and mortality in patients with pulmonary arterial hypertension. However, the long-term effects of these medications on PAH-CHD patients remain somewhat uncertain, necessitating treatment plans largely founded on the clinical experience of the healthcare providers. The aim of this review is to summarize the current evidence and future perspectives regarding treatment strategies for PAH-CHD to help better guide management of this complex disease.
The role of serum lipoprotein(a) levels in bioprosthetic aortic valve degeneration
Fariña, Juliana, Roarke, M., Barry, Timothy, Sweeney, John P., Fortuin, David, Lester, Steven J., Oh, Jae K. , Marcotte, F, Pereyra, Milagros , Pereyra, Milagros , Farina, J, Chao, Chieh‐Ju , Said, E, Alsidawi, Said , Sell‐Dottin, Kristen , Ayoub, C, Arsanjani, Reza

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.1616 Get It

Abstract Introduction Lipoprotein(a) [Lp(a)] is associated with an increased incidence of aortic stenosis. Bioprosthetic aortic valve degeneration and native aortic stenosis share similar pathological mechanisms. Evidence regarding the role of serum Lp(a) concentrations in bioprosthetic aortic valve degeneration is lacking. Purpose To evaluate the association between serum Lp(a) concentrations and bioprosthetic aortic valve degeneration. Methods In this retrospective multicenter study, consecutive patients who underwent a bioprosthetic aortic valve replacement between Jan-2010 and Dec-2020 and had a preoperatory serum Lp(a) measurement were included. A baseline transthoracic echocardiography (TTE) was performed following the aortic valve replacement and a follow-up TTE was performed at least 24 months after the baseline study to determine the presence of bioprosthetic valve degeneration. Significant degeneration was defined as: (a) an increase >10 mmHg in mean bioprosthetic aortic valve gradient from baseline status + a decrease in effective orifice area + a decrease in Doppler velocity index + exclusion of clinically thrombotic leaflet thickening, OR (b) new moderate or severe prosthetic aortic regurgitation (if the main component was periprosthetic, then it was not considered). Lp(a) concentrations were compared between patients with and without degeneration and regression analysis was conducted to investigate the association between bioprosthetic valve degeneration and Lp(a) levels. Results In total, 211 cases were included (mean age 74.1 ±9.4 years, 72.0% males, 29.9% transcatheter aortic valve replacements) (Figure 1). Median time between baseline and follow-up TTE was 5.0 (IQR 3.7) years. Bioprostheses degeneration was observed in 33 (15.6%) patients at follow-up. Median serum levels of Lp(a) were significantly higher in the patients affected by degeneration versus non-affected cases (50.0 vs 15.7 mg/dl, p=0.003). In the regression analysis, high Lp(a) levels (≥30 mg/dl) were associated with degeneration both in a univariate analysis (OR 4.8, 95%CI 2.2-10.9, p<0.001) and multivariate analysis adjusted by other risk factors for bioprostheses degeneration (age, sex, hypertension, smoking, patient prosthesis mismatch, creatinine levels, and body surface area) (OR 5.2, 95%CI 2.1-12.8, p<0.001). Conclusion Serum Lp(a) concentrations seem to be a risk factor for bioprosthetic aortic valve degeneration (Figure 2). There is an increasing need to accurately predict bioprosthetic aortic valve degeneration and to develop novel methods and treatments to increase their durability. Prospective studies are needed to confirm these findings and to investigate whether lowering Lp(a) could slow bioprostheses degradation.Population characteristicsLp(a) and bioprostheses degeneration
GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle
Marcotte, George R. , Miller, Matthew J. , Ryan, Zachary C. , Strub, Matthew D. , Vanderboom, Patrick M. , Heppelmann, Carrie J. , Chau, Sarah, Ruff, Zachary D. Von, Kilroe, Sean P. , McKeen, Andrew T., Dierdorff, Jason M., Stern, Jennifer I. , Nath, Karl A. , Ebert, Scott M. , Adams, Christopher M. , Ebert, Scott M. , Adams, Christopher M , Kunz, Hawley , Chau, Sarah, Grueter, Chad Eric , Lira, Vitor Agnew , Judge, Andrew R. , Rasmussen, Blake B. , Nair, K. Sreekumaran , Lanza, Ian R.

Mayo Clinic

JCI Insight | October 10, 2023 | Volume: 8 | Issue: 22 | Pages: No page available

10.1172/jci.insight.171772 | PMID 37815864 Get It

Aging and many illnesses and injuries impair skeletal muscle mass and function, but the molecular mechanisms are not well understood. To better understand the mechanisms, we generated and studied transgenic mice with skeletal muscle–specific expression of growth arrest and DNA damage inducible α (GADD45A), a signaling protein whose expression in skeletal muscle rises during aging and a wide range of illnesses and injuries. We found that GADD45A induced several cellular changes that are characteristic of skeletal muscle atrophy, including a reduction in skeletal muscle mitochondria and oxidative capacity, selective atrophy of glycolytic muscle fibers, and paradoxical expression of oxidative myosin heavy chains despite mitochondrial loss. These cellular changes were at least partly mediated by MAP kinase kinase kinase 4, a protein kinase that is directly activated by GADD45A. By inducing these changes, GADD45A decreased the mass of muscles that are enriched in glycolytic fibers, and it impaired strength, specific force, and endurance exercise capacity. Furthermore, as predicted by data from mouse models, we found that GADD45A expression in skeletal muscle was associated with muscle weakness in humans. Collectively, these findings identify GADD45A as a mediator of mitochondrial loss, atrophy, and weakness in mouse skeletal muscle and a potential target for muscle weakness in humans.